Celldex Therapeutics (NASDAQ:CLDX) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Celldex Therapeutics (NASDAQ:CLDX) in a research report report published on Wednesday morning,Benzinga reports. They currently have a $80.00 price objective on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Celldex Therapeutics’ FY2025 earnings at ($2.99) EPS.

Several other analysts also recently weighed in on CLDX. Wolfe Research downgraded shares of Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a report on Friday, September 27th. The Goldman Sachs Group began coverage on Celldex Therapeutics in a report on Monday, September 30th. They issued a “neutral” rating and a $45.00 price objective on the stock. Wells Fargo & Company upgraded Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday, September 26th. Cantor Fitzgerald reissued an “overweight” rating and issued a $67.00 price target on shares of Celldex Therapeutics in a report on Monday, September 16th. Finally, Citigroup began coverage on Celldex Therapeutics in a report on Monday, October 7th. They set a “buy” rating and a $70.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Celldex Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $62.25.

Celldex Therapeutics Price Performance

NASDAQ:CLDX opened at $27.02 on Wednesday. The firm has a market cap of $1.79 billion, a price-to-earnings ratio of -10.51 and a beta of 1.60. The firm’s fifty day moving average price is $30.21 and its 200 day moving average price is $34.92. Celldex Therapeutics has a 1-year low of $22.93 and a 1-year high of $53.18.

Insider Buying and Selling

In other Celldex Therapeutics news, CEO Anthony S. Marucci acquired 11,500 shares of the stock in a transaction that occurred on Monday, November 11th. The shares were purchased at an average cost of $26.82 per share, with a total value of $308,430.00. Following the purchase, the chief executive officer now owns 40,284 shares in the company, valued at approximately $1,080,416.88. The trade was a 39.95 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 3.80% of the stock is currently owned by insiders.

Institutional Trading of Celldex Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. KBC Group NV raised its position in shares of Celldex Therapeutics by 31.2% during the 3rd quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 495 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Celldex Therapeutics in the second quarter worth $76,000. CANADA LIFE ASSURANCE Co raised its holdings in shares of Celldex Therapeutics by 26.4% in the first quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock worth $192,000 after acquiring an additional 955 shares during the last quarter. Ameritas Investment Partners Inc. lifted its position in shares of Celldex Therapeutics by 34.3% in the first quarter. Ameritas Investment Partners Inc. now owns 6,198 shares of the biopharmaceutical company’s stock valued at $260,000 after acquiring an additional 1,582 shares in the last quarter. Finally, Quest Partners LLC boosted its stake in shares of Celldex Therapeutics by 1,364.9% during the second quarter. Quest Partners LLC now owns 7,383 shares of the biopharmaceutical company’s stock valued at $273,000 after acquiring an additional 6,879 shares during the last quarter.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.